Broustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J, Pris J, Bernard P, Charrin C, Wen Z Q
Hôpital Haut Leveque, Pessac, France.
Eur J Cancer. 1991;27 Suppl 4:S18-21. doi: 10.1016/0277-5379(91)90558-u.
In order to compare the effects of interferon versus hydroxyurea for the treatment of chronic myelogenous leukaemia (CML), 58 CML patients, having received no previous treatment, were randomized into two treatment groups (hydroxyurea or interferon) for an open multicentre study from 1 May 1987 until 1 July 1990. Fifty patients were evaluable: 24 in the interferon group and 26 in the hydroxyurea group. Haematological response was obtained in 16/24 interferon-treated patients and 23/26 hydroxyurea patients. Failure to obtain haematological remissions occurred in eight of 24 interferon-treated patients and in three of 26 hydroxyurea patients. Four interferon-treated patient failures and one hydroxyurea-treated failure were due to drug intolerance. Progression occurred in one interferon-treated patient and in three patients given hydroxyurea. Fourteen of 16 patients in the interferon group and 17/23 in the hydroxyurea group continue on study and show no progression.
为比较干扰素与羟基脲治疗慢性粒细胞白血病（CML）的效果，58例未接受过治疗的CML患者于1987年5月1日至1990年7月1日被随机分为两个治疗组（羟基脲组或干扰素组），进行一项开放性多中心研究。50例患者可进行评估：干扰素组24例，羟基脲组26例。接受干扰素治疗的24例患者中有16例获得血液学缓解，接受羟基脲治疗的26例患者中有23例获得缓解。接受干扰素治疗的24例患者中有8例未获得血液学缓解，接受羟基脲治疗的26例患者中有3例未获得缓解。接受干扰素治疗的患者中有4例治疗失败，接受羟基脲治疗的患者中有1例治疗失败是由于药物不耐受。接受干扰素治疗的患者中有1例病情进展，接受羟基脲治疗的患者中有3例病情进展。干扰素组16例患者中的14例以及羟基脲组23例患者中的17例继续参与研究且未出现病情进展。
